back to US directory
us clinical guidance

Established primary hypothyroidism: hormone replacement

A source-bounded ATA hormone-replacement summary for established primary hypothyroidism; diagnostic testing for suspected disease is outside scope.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Nonpregnant adults with an already established diagnosis of primary hypothyroidism. The 2014 ATA source is a hormone-replacement guideline; the attached ATA library index is not evidence for a diagnostic testing sequence. Suspected but unconfirmed thyroid dysfunction, nodules, cancer, thyrotoxicosis, pregnancy, central pituitary disorders and myxedema-coma critical care are outside this summary.
sources for this section:ATA hypothyroidism 2014

The Bottom Line

  • Do not use this page as a diagnostic testing algorithm: the attached treatment guideline and ATA index do not establish which initial or confirmatory tests to order for suspected thyroid dysfunction.
  • Before applying replacement recommendations, verify that primary hypothyroidism has been established under an exact current diagnostic authority and that pregnancy, central disease or another special pathway is not the relevant question.
  • Levothyroxine is the standard replacement for primary hypothyroidism; choose an individualized starting dose from age, body size, residual function, pregnancy status and coronary or rhythm risk.
  • Counsel on consistent administration and separation from interfering food, supplements or medicines, then titrate from symptoms and a correctly timed TSH rather than frequent unscheduled changes.
  • Do not use desiccated thyroid extract, liothyronine or compounded products as an automatic response to persistent nonspecific symptoms; reassess diagnosis, dose, adherence, interactions and alternative causes first.
sources for this section:ATA hypothyroidism 2014

Practical clinical workflow

1
Confirm the documented diagnosis and treatment indication, pregnancy status, cardiac risk and current preparation; reconcile prescriptions, supplements and administration factors that can alter replacement exposure.
2
If the diagnosis is uncertain, results are discordant or central disease is possible, stop this replacement-only workflow and retrieve an exact current diagnostic authority or specialist assessment rather than inferring a test sequence from the ATA index.
3
For overt primary hypothyroidism, begin levothyroxine at an individualized dose, record the product and administration plan, and arrange TSH reassessment after steady state rather than within a few days.
4
After each dose change, recheck at the source-supported interval; once stable, monitor periodically and sooner with major weight change, interacting therapy, pregnancy, symptoms or adherence change.
5
Refer or obtain specialist input for central disease, pregnancy, severe cardiac disease, unusual assay discordance, treatment-refractory abnormal results or consideration of nonstandard hormone therapy.
sources for this section:ATA hypothyroidism 2014

Safety boundaries and escalation

  • Hypothermia, altered consciousness, hypoventilation, bradycardia, hypotension or severe hyponatremia with suspected myxedema requires emergency treatment and endocrine or critical-care input.
  • Exclude or treat adrenal insufficiency before thyroid hormone in a patient at meaningful adrenal-crisis risk because replacement can precipitate decompensation.
  • Over-replacement increases atrial arrhythmia and bone risk; palpitations, chest pain or a suppressed TSH should trigger timely review rather than continued dose escalation for fatigue.
  • Pregnancy requires prompt, separate ATA guidance and tighter monitoring; radioactive iodine and antithyroid treatment decisions are outside this hypothyroidism page.
sources for this section:ATA hypothyroidism 2014ATA thyroid guidelines

Localization

Use the attached ATA source only for its hormone-replacement scope and current FDA-regulated products. The ATA guidelines-and-statements page is an index, not a diagnostic recommendation.
sources for this section:ATA hypothyroidism 2014

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Thyroid Association Task Force on Thyroid Hormone ReplacementGuidelines for the Treatment of HypothyroidismDOI 10.1089/thy.2014.0028 路 published 2014-09-29 路 accessed 2026-08-20
    view source
  2. American Thyroid AssociationAmerican Thyroid Association Guidelines and Statementscurrent guideline library checked 2026-08-20 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.